Literature DB >> 6203697

The toxicological evaluation of tallysomycin s10b--biosynthetic tallysomycin derivative.

R A Buroker, C R Comereski, D Barnett, R S Hirth, H Madissoo, G H Hottendorf.   

Abstract

Tallysomycin S10b, a biosynthetic derivative of tallysomycin B, was subjected to intravenous toxicologic studies in mice and dogs. LD50 and LD10 values from lethality studies in mice were utilized to establish dose levels for single and five daily dose toxicity studies in mice and dogs. Nephrotoxicity was the most consistent and prominent drug-related alteration in single and multiple dose studies in both species and was considered the dose limiting toxicity. Other toxicities included pulmonary toxicity, lymphopenia and necrosis of extremities in mice and dogs and testicular degeneration and focal vacuolation of adrenal cortical cells in the dog. Bleomycin was administered to dogs as a reference control agent at a single dose of 270 mg/m2 which was approximately equivalent to the highest tallysomycin S10b dose of 240 mg/m2. Tallysomycin S10b showed a greater nephrotoxic potential than bleomycin at earlier time periods. However, at termination there was no meaningful difference in the degree of chronic nephrotoxicity. The pulmonary toxicity of both drugs was comparable.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203697     DOI: 10.3109/01480548409035107

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  5 in total

1.  Phase II study of tallysomycin S10b in patients with advanced colorectal cancer.

Authors:  C Nicaise; J Ajani; P Goudeau; M Rozencweig; B Levin; I Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A radioimmunoassay procedure for tallysomycin S10b in human plasma and urine.

Authors:  R C Gaver; C W Dixon; R D Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Tallysomycin S10b--a phase I trial.

Authors:  P G Sørensen; H Pedersen; H V Clausen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Phase II study of tallysomycin S10b in patients with advanced head and neck cancer.

Authors:  C Nicaise; W K Hong; W Dimery; J Usakewicz; M Rozencweig; I Krakoff
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

5.  Tallysomycin S10b: experimental antitumor activity and toxicity.

Authors:  J E Schurig; W C Rose; R S Hirth; A Schlein; J B Huftalen; A P Florczyk; W T Bradner
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.